First Quarter 2024 Financial Results Released by Samsung Biologics
Samsung Biologics (KRX: 207940.KS), a leading global contract development and manufacturing organization (CDMO), has unveiled its financial performance for the first quarter of fiscal year 2024. John Rim, CEO and…